Johns Hopkins School of Medicine

Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors

Retrieved on: 
Monday, July 10, 2023
Faculty, Intellectual property, University, Therapy, American Heart Association, FACC, American Society for Clinical Investigation, Disclosure, American Association for Physician Leadership, NAI, Research, Bangladesh Technical Education Board, Translation, Invention, Shimaa Hashad, Harvard Medical School, Entrepreneurship, National academy, Cardiology, Transplant, Hospital, Johns Hopkins School of Medicine, Johns Hopkins, Society, BA, Pharmaceutical industry, Management, Physician, Ageing, Brigham, MD

Dr. Hare was officially inducted into NAI on June 27, 2023, at the Academy’s annual meeting in Washington, D.C.

Key Points: 
  • Dr. Hare was officially inducted into NAI on June 27, 2023, at the Academy’s annual meeting in Washington, D.C.
    "On behalf of everyone at Longeveron, I congratulate Josh on this prestigious honor,” said Wa’el Hashad, Chief Executive Officer of Longeveron.
  • “That’s just one reason why cell-based therapeutics such as Lomecel-B™ are so important and why all of us at Longeveron are focused on realizing this asset’s full potential.
  • Dr. Hare has also served in numerous leadership roles at the American Heart Association and at the Center for Scientific Review of the National Institutes of Health.
  • Dr. Hare is also a co-founder of Vestion, Inc., and Heart Genomics, LLC, companies that hold cardio-related intellectual property.

Braven Launches New Unit to Invest In the Next Generation of Healthcare & Life Science Innovators

Retrieved on: 
Friday, July 7, 2023
Insurance, Finance, FDA, Professional Services, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, IBM, Information exchange, IQVIA, Association of British HealthTech Industries, BlackRock, Intelligence, Unit, MIT, Investment, Johnson & Johnson, Abecassis, Machine learning, Drug discovery, Ecosystem, Johns Hopkins School of Medicine, Frazier Healthcare Partners, Pharmaceutical industry, Cryptocurrency, Braven

Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the firm’s unique ‘co-building’ investment strategy.

Key Points: 
  • Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the firm’s unique ‘co-building’ investment strategy.
  • "Across healthcare and life sciences, there are countless opportunities for innovation.
  • To augment the Unit's capabilities, Braven has enlisted a team of specialized fellows with expertise spanning from pharma development to healthcare provision.
  • Braven is an early-stage investment firm focused on breakthrough innovation within regulated ecosystems, starting with financial services, insurance, and healthcare.

AMERICAN SKIN ASSOCIATION ANNOUNCES 2023 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES

Retrieved on: 
Monday, July 3, 2023
ASA, Skin, University of Massachusetts, Icahn School of Medicine at Mount Sinai, Eastern Virginia Medical School, Skin cancer, Atopic dermatitis, Prognosis, Research, Mount Sinai, Doctor of Philosophy, Melanoma, Depigmentation, Name, Dermatology, MAC, Physician, HMF, Diagnosis, Patient, Johns Hopkins School of Medicine, Melanoma Research, Pharmaceutical industry, Psoriasis, MD, Vitiligo, Medicine

NEW YORK, July 3, 2023 /PRNewswire/ -- American Skin Association has announced the names of the four Research Scholar Awards.

Key Points: 
  • NEW YORK, July 3, 2023 /PRNewswire/ -- American Skin Association has announced the names of the four Research Scholar Awards.
  • In addition, one research grant and nine medical student grants — made possible through the generosity of individuals, foundations, and corporations — were also announced.
  • "These grants support cutting-edge dermatological research that is crucial in advancing ASA's goal of defeating skin cancers like melanoma.
  • ASA provides significant research awards to established investigators and medical students studying melanoma, non-melanoma skin cancer, and other skin diseases.

Cardiometabolic Health Congress Hosts 2023 Women's Masterclass in California

Retrieved on: 
Thursday, June 29, 2023
Dyslipidemia, Education, Cardiovascular disease, Johns Hopkins School of Medicine, Medicine, CHCP, Organization, CMHC, MHS, Student, MD, Nature, Yoga, Patient, Menopause, Faculty, American College, Society, News, Nursing, Tourism, Woman

Boca Raton, FL, June 29, 2023 (GLOBE NEWSWIRE) -- Informed by topics most relevant to cardiometabolic health providers, medical education leader Cardiometabolic Health Congress (CMHC) has announced another iteration of its Women’s Cardiometabolic Health and Wellness Masterclass .

Key Points: 
  • Boca Raton, FL, June 29, 2023 (GLOBE NEWSWIRE) -- Informed by topics most relevant to cardiometabolic health providers, medical education leader Cardiometabolic Health Congress (CMHC) has announced another iteration of its Women’s Cardiometabolic Health and Wellness Masterclass .
  • "As a women's cardiovascular health leader specializing in lipidology, I know firsthand that women’s cardiovascular and cardiometabolic care must be approached with unique tools and strategies.
  • "We are pleased to announce our partnerships for the 2023 Women's Cardiometabolic Health and Wellness Masterclass.
  • The experts at CMHC are committed to creating education for practicing clinicians, students, and patients interested in the quickly evolving field of cardiometabolic health.

National Cancer Center Announces Recipients of 2023-24 Research Fellowship Awards

Retrieved on: 
Thursday, June 29, 2023
Research, Philanthropy, Pharmaceutical, Oncology, Hospitals, University, Genetics, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, UPMC Hillman Cancer Center, DNA, Cleveland Clinic, Duke University Hospital, University of Pittsburgh, NCC, Brain, Therapy, Swansea University Medical School, Prostate cancer, Follicular lymphoma, Johns Hopkins School of Medicine, Cancer, Nebraska Medicine, Coronavirus Scientific Advisory Board, Woman, DNA repair, University of Nebraska Medical Center, Breast, University of California, Colon, Harvard Medical School, National Cancer Center, City, Prostate Cancer Foundation, Melanoma, Rockefeller University, Baylor College of Medicine, Diagnosis, New York University Grossman School of Medicine, Tobacco Products Scientific Advisory Committee, Dana–Farber Cancer Institute, Pharmaceutical industry, Interior design, Doctor of Philosophy, New York University

The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • National Cancer Center is delighted to report that total funding for the 2023-24 year grew by 9.4% to an annual record of $768,000.
  • “For 70 years, National Cancer Center has sought to identify and fund promising projects by the best up-and-coming cancer research fellows,” said Regina English, Executive Director of the National Cancer Center.
  • The NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; the Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which focuses on research showing particular promise for brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics.

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

Retrieved on: 
Thursday, June 29, 2023
Research, Medical Devices, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Pancreatic cancer, SBRT, Arm, PI, IV, Gastrointestinal cancer, TAMP, Life, Progression-free survival, LAPC, Trans, ESMO, Survival, Cancer, IA, Toxicity, PFS, Sale, Johns Hopkins School of Medicine, Patient, Risk, Diagnosis, Principal, Death, Micro, Disease, Pharmaceutical industry, Medical imaging

The interim analysis demonstrated an eight-month median PFS benefit, 15 versus 7 months, in delaying the progression of cancer for patients receiving treatment with RenovoGem versus standard-of-care.

Key Points: 
  • The interim analysis demonstrated an eight-month median PFS benefit, 15 versus 7 months, in delaying the progression of cancer for patients receiving treatment with RenovoGem versus standard-of-care.
  • PFS is the measure of the length of time from study randomization to either death or progression of disease.
  • “Clinical practice has been waiting decades for a meaningful advancement in the standard of care for pancreatic cancer treatment, with less toxicity and better outcomes.
  • The TIGeR-PaC Data Monitoring Committee met and determined the interim data is promising and warrants continuation of this pivotal trial.

Truvian Health to Present Performance of Blood Testing Solution from Recent Multisite Clinical Study at the American Association of Clinical Chemistry Annual Scientific Meeting

Retrieved on: 
Wednesday, June 28, 2023
Medical Devices, Hospitals, Clinical Trials, Health Technology, Practice Management, Other Health, Biometrics, Biotechnology, General Health, Health, Maintenance, AACC, Immunoassay, Trial of the century, Death, Patient, Blood, Hematology, Johns Hopkins School of Medicine, DEKA, Development corporation, Conditional sentence, Disease, Medical device, Pharmaceutical industry, Pathology

“Chronic diseases account for 41 million deaths each year – 74% of deaths globally – and present a significant cost burden that forces millions into poverty1.

Key Points: 
  • “Chronic diseases account for 41 million deaths each year – 74% of deaths globally – and present a significant cost burden that forces millions into poverty1.
  • As a result, we can reduce the time from blood draw results for an expansive panel of tests – quickly providing actionable insights where and when they are needed.
  • With an initial testing panel of more than 30 assays, the Truvian Platform can run the most commonly ordered tests that account for 90% of blood test orders.
  • To continue to advance the Truvian Platform, currently in late-stage development, the company recently expanded its advisory board.

Johns Hopkins Center for Psychedelic & Consciousness Research Names New Director

Retrieved on: 
Tuesday, June 20, 2023
Psilocybin, Psychology, Cognition, Associate Director of National Intelligence and Chief Information Officer, Music, Human, University, Systems neuroscience, Johns Hopkins School of Medicine, Clinical trial, University of California, Davis, Research, LSD, Psychedelic drug, Doctor of Philosophy, Associate, Bangladesh Technical Education Board, Claustrum, CPRC, DSM-IV codes, Johns Hopkins University, UC, Patient, Pharmacology, Johns Hopkins Center for Health Security, Psychiatry, Behavioural sciences, Faculty, MPH, Consciousness, Management, Pharmaceutical industry, Nursing, MD

BALTIMORE, June 20, 2023 /PRNewswire/ -- The Johns Hopkins Center for Psychedelic & Consciousness Research (CPRC) has announced the appointment of Frederick S. Barrett, PhD, as its new Director, effective immediately.

Key Points: 
  • BALTIMORE, June 20, 2023 /PRNewswire/ -- The Johns Hopkins Center for Psychedelic & Consciousness Research (CPRC) has announced the appointment of Frederick S. Barrett, PhD, as its new Director, effective immediately.
  • He has been conducting psychedelic research at Johns Hopkins University since 2013.
  • Johns Hopkins Department of Psychiatry and Behavioral Sciences Director, James B. Potash, MD, MPH, said, "I couldn't be more pleased to welcome Dr. Barrett to this critically important role as the CPCR's new Director.
  • I am confident he will drive the CPCR to continued success as a world leader in psychedelic research."

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

Retrieved on: 
Tuesday, June 20, 2023
Laboratory, Drug development, Professional Football Compensation Committee, University, Bureau of Oceans and International Environmental and Scientific Affairs, CSU, Horizon Therapeutics, Abbott Laboratories, Senior advisor, Medication, Champaign–Urbana metropolitan area, Technical Guidelines Development Committee, Harvard Medical School, Massachusetts Eye and Ear, Partner, AbbVie, Risk, Syndrome, Thakeham, Ophthalmology, R, Research, CD117, Therapy, Neurology, Johns Hopkins School of Medicine, Pharmaceutical industry, Upadacitinib, Biochemistry, Jasper

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper’s Board of Directors. Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee. Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees. Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.

Key Points: 
  • Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee.
  • Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees.
  • Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.
  • He was most recently a Senior Advisor to Horizon Therapeutics and Vice President of Scientific Affairs and Head of AbbVie Ventures.

Orthopedic Care Partners Announces Affiliation with American Spine & Orthopaedic Institute

Retrieved on: 
Tuesday, June 13, 2023
Heart, National Platform, Mayo Clinic, Elective surgery, North American Spine Society, Nemours Children's Hospital, Delaware, Pathology, Spine, Johns Hopkins School of Medicine, United States Armed Forces, University of Maryland Rehabilitation & Orthopaedic Institute, OCP, MD, Patient, Clinical professor, Desert Uniforms, Patches, and Insignia of the US Armed Forces, Trauma, Dentistry, Medical device, Medicine

FORT LAUDERDALE, Fla., June 13, 2023 /PRNewswire/ -- Orthopedic Care Partners (OCP), a leading orthopedic practice management platform, today announced a strategic affiliation with the American Spine & Orthopaedic Institute (ASOI), a renowned practice specializing in complex adult and pediatric spine pathology, based in Orlando, FL.

Key Points: 
  • Transaction Expands OCP's National Platform, Adding a Specialty in Complex Adult and Pediatric Spine Pathology
    FORT LAUDERDALE, Fla., June 13, 2023 /PRNewswire/ -- Orthopedic Care Partners ( OCP ), a leading orthopedic practice management platform, today announced a strategic affiliation with the American Spine & Orthopaedic Institute ( ASOI ), a renowned practice specializing in complex adult and pediatric spine pathology, based in Orlando, FL.
  • Dr. Manzanares and his team are recognized for their three primary areas of expertise: minimally invasive spinal surgery, advanced spine reconstruction, and sports-related injury.
  • This affiliation fits perfectly with our strategy of partnering with market-leading practices that offer exceptional and comprehensive care."
  • Dr. Manzanares added, "Our affiliation with OCP will enhance our mission of providing world-class spinal and orthopaedic care to our patients in central Florida.